Showing results (221-230 of 280) with videos related to
Sort By:
Pageof 28
Cancer Gene Therapy|September 13, 2020
Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytesSadia Zafar, Dafne Carolina Alves Quixabeira, Tatiana Viktorovna Kudling, et al.The Journal of Gene Medicine|September 16, 2004
Evaluation of tissue-specific promoters in carcinomas of the cervix uteriDaniel T Rein, Martina Breidenbach, Dirk M Nettelbeck, et al.Journal of Virology|March 30, 2012
A new human DSG2-transgenic mouse model for studying the tropism and pathology of human adenovirusesHongjie Wang, Ines Beyer, Jonas Persson, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|August 30, 2003
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirusAnna Kanerva, Kurt R Zinn, Tandra R Chaudhuri, et al.Oncotarget|February 26, 2015
Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapyOtto Hemminki, Suvi Parviainen, Juuso Juhila, et al.Human Molecular Genetics|July 27, 2010
Mitochondrial myopathy induces a starvation-like responseHenna Tyynismaa, Christopher J Carroll, Nuno Raimundo, et al.Cancer Research|March 13, 2002
Treatment of ovarian cancer with a tropism modified oncolytic adenovirusGerd J Bauerschmitz, John T Lam, Anna Kanerva, et al.The Journal of Gene Medicine|October 20, 2004
Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapyJohn T Lam, Anna Kanerva, Gerd J Bauerschmitz, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2013
Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirusAnna Kanerva, Petri Nokisalmi, Iulia Diaconu, et al.Nature Medicine|December 15, 2010
Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14Hongjie Wang, Zong-Yi Li, Ying Liu, et al.Pageof 28